Mentioned:
A publicly traded company on the Nasdaq is making new potential breakthroughs in influenza. And they’re doing it through leveraging Advanced Micro Devices’ hardware and software for artificial intelligence workloads.
What’s happening:
- MindWalk Holdings (NASDAQ: HYFT) has successfully identified a single, shared functional constraint in influenza that is present across human, avian and swine strains of Influenza A and Influenza B
Why it matters:
- Influenza is one of the most difficult viruses to develop therapeutics and vaccines for due to constant mutations and the rapid formation of new strains
Going deeper:
- MindWalk Holdings has a partnership with Advanced Micro Devices (NASDAQ: AMD) that leverages Advanced Micro Devices’ MI300X GPUs, EPYC CPUs and their ROCm software stack to run large biology models and accelerate potential breakthroughs in drug discovery
- MindWalk Holdings has publicly stated they plan to begin pre-clinical drug validation for their influenza program and pursue a strategic development partnership with a pharmaceutical company
The intrigue:
- Advanced Micro Devices previously made waves when they publicly stated that their MI300X GPUs, EPYC CPUs and ROCm software stack have enabled MindWalk Holdings to reduce the computational time for their biologics discovery workloads from months into just hours by being able to run large artificial intelligence models significantly faster and using their full stack architecture to optimize workflows
